T1	Participants 58 100	women with locally advanced breast cancer:
T2	Participants 248 275	patients with breast cancer
T3	Participants 415 474	women undergoing neoadjuvant chemotherapy for breast cancer
T4	Participants 554 614	between March 17, 2003, and May 19, 2006, at a single centre
T5	Participants 616 831	Eligible patients had clinical stage II-III (> or = T2 and/or > or = N1) newly diagnosed breast cancer, Eastern Cooperative Oncology Group performance status of 0 or 1, and normal cardiac, renal, and liver function.
T6	Participants 832 841	120 women
T7	Participants 1460 1505	120 patients initially enrolled, one withdrew
